State of scientific research: the contemporary landscape of methylene blue

General context: from oblivion to revival

Why this renewed interest?

Three converging factors have rekindled scientific attention on this 150-year-old compound:

1. Technological advances: modern molecular biology (genetic sequencing, confocal microscopy, mass spectrometry) enables studies of the dye that the 20^th century could not undertake.
2. The crisis of neurodegenerative diseases: faced with the partial failure of conventional approaches against Alzheimer's and Parkinson's, the scientific community is exploring alternative avenues. Methylene blue emerges as a promising molecule for these fields.
3. Rediscovery of mitochondrial properties: the growing importance attached to mitochondrial dysfunction in chronic diseases (cancer, neurodegeneration, diabetes) positions methylene blue as a potential therapeutic candidate.

Major fields of current research

1. Neuroprotection and neurodegenerative diseases

Alzheimer's disease

Hypothesis: the accumulation of misfolded proteins (amyloid-beta, tau) in the brain causes neurodegeneration. Methylene blue could intervene through several mechanisms:

• Protein aggregation: preventing the self-assembly of toxic proteins
• Antioxidation: reducing chronic oxidative stress
• Mitochondrial restoration: improving neuronal energy metabolism

State of the evidence:

• In vitro: several studies show partial inhibition of amyloid aggregation
• Transgenic animal models: slight improvement in markers of neurotoxicity
• Human clinical trials: very limited (a few small cohorts); mixed results

Example of a recent study: a small randomised controlled trial (2018-2020, ~40 patients) tested methylene blue in patients with moderate Alzheimer's. Results: a slight slowing of cognitive decline compared with placebo, but not statistically significant after multiple-comparison correction.

Conclusion: promising in vitro, but solid clinical evidence is lacking. Rigorous, well-powered trials are needed.

Parkinson's disease

Hypothesis: dysfunction of dopaminergic mitochondria. The dye could:

• Accept failing mitochondrial electrons
• Reduce the formation of dopamine-related free radicals

Status: research at an exploratory stage. Few clinical trials published. Animal data are encouraging but translationally uncertain.

2. Anticancer photodynamic therapy

Mechanism and promise

Unlike neuroprotective applications (based on redox), photodynamic therapy (PDT) exploits the ability of methylene blue to generate singlet oxygen upon visible illumination.

Target: cutaneous and mucosal cancers (endoscopically accessible).

Theoretical advantages:

• Spatial targeting of the light
• Little systemic toxicity
• Potential against chemotherapy-resistant cancers

State of the clinical evidence

In vitro: efficacy demonstrated against a range of cancer cell lines (melanoma, hepatocellular carcinoma, breast cancer).

Animal models: tumour inhibition in mouse xenografts (models in which human cancer is implanted).

Clinical trials: very limited. A few pilot studies on non-melanocytic skin cancers and oral cancers. Results: some patients show a good response, others do not. The heterogeneity suggests that the dye is not suitable for all cancers.

Challenges:

• Optimisation of the illumination wavelength
• Critical dosing of the dye and illumination timing
• Comparison with existing photodynamic therapies (porphyrins) is lacking

Conclusion: an interesting approach, but far from a standard therapy. Research continues in academic settings without broad clinical adoption.

3. Mitochondrial dysfunction and energy metabolism

Mitochondrial myopathies

Target population: patients carrying genetic mutations affecting the mitochondrial complexes.

Hypothesis: methylene blue would bypass complex failures by directly accepting electrons.

Evidence:

• In vitro: demonstrated in fibroblasts from mutant patients
• Animal models: positive results in mice with targeted mitochondrial mutations
• Clinical: a few anecdotal case reports, no rigorous controlled trial

Status: high theoretical promise, minimal clinical evidence. A field in which research could advance rapidly with appropriate funding.

Type 2 diabetes and insulin resistance

Hypothesis: pancreatic mitochondrial dysfunction reduces insulin sensitivity. Would the dye improve this situation?

Status: pre-clinical research only. Very few animal studies, zero human trials.

4. Leukaemia and haematological malignancies

Cytotoxic potential

Methylene blue shows in vitro cytotoxicity against certain leukaemic cell lines (particularly lymphoblastic leukaemias). The mechanism is not entirely clear — perhaps through oxidative stress or metabolic disruption.

Clinical status: no trials in patients. A largely unexplored field. The lack of penetration of the dye across the blood-brain barrier could limit its usefulness against CNS leukaemias.

5. Oxidative stress and chronic inflammation

Accelerated ageing and cellular senescence

Hypothesis: the reduction of oxidative stress by the dye would slow cellular ageing.

Evidence: encouraging in vitro studies, zero longitudinal human trials.

Reasonable scepticism: ageing is multifactorial. Reducing oxidative stress alone will probably not suffice.

Methodology of contemporary research

Types of studies under way

In vitro studies: cell cultures, organoids. Fast and inexpensive, but limited in biological complexity.

Animal models: mainly rodents (mice, rats). They allow toxicity and efficacy testing in vivo. Translatability to humans is imperfect.

Human clinical trials:

• Phase I: safety in healthy volunteers. A few completed trials, a relatively good safety profile.
• Phase II: efficacy in patients. Very few completed trials published.
• Phase III: comparative efficacy versus standard of care. None for methylene blue (as far as is known).

International clinical registries

Consult ClinicalTrials.gov (the US registry) and equivalent registries (EU, China) for ongoing trials. A search for "methylene blue" reveals roughly 30-50 active or completed trials worldwide — a low figure compared with mainstream oncological molecules.

Major gaps in the scientific evidence

1. Absence of large clinical trials

No large-scale randomised multicentre trial (> 500 patients) for any of the dye's indications. This is a critical gap for establishing real efficacy versus placebo.

2. Uncertain dosing and pharmacokinetics

What dose of the dye actually reaches the mitochondria? For how long does it persist? Does it vary between patients? Few systematic pharmacokinetic studies.

3. Animal-to-human translatability

Promising results in mice do not always translate to humans. The complexity of the human brain and the plurality of disease aetiologies make extrapolation difficult.

4. Incomplete mechanisms of action

For many of the proposed applications, the exact mechanism by which the dye helps remains unclear. Redox? Antioxidation? Off-target effects? Mechanistic clarification would guide the trials.

Current scientific consensus

Here is what the majority of researchers agree upon:

• ✅ Methylene blue possesses real, measurable chemical and biological properties.
• ✅ The pre-clinical evidence is encouraging in several fields.
• ⚠️ Solid clinical evidence is lacking, because funding for a product without profitability is lacking.
• ⚠️ No consensus on the best priority clinical indication.
• ⚠️ Urgent need for well-designed and well-funded clinical trials. But the pharmaceutical industry has no interest in this, as the molecule is no longer patentable.

For a particularly critical analysis of the Schwartz theories, consult our page dedicated to metabolic approaches.

Future prospects

Short term (2025-2027)

• Completion of the ongoing Phase II trials (Alzheimer's neuroprotection, PDT for skin cancers)
• Possible emergence of Phase III trials if results are encouraging
• Clarification of the molecular mechanisms through advanced techniques (proteomics, metabolomics)

Medium term (2027-2032)

• Potentially a first regulatory approval for a non-standard indication
• Combinations with other therapeutic agents tested
• Long-term studies on safety and tolerability

Conclusion

Current scientific research on methylene blue is in transition: a shift from the exploratory pre-clinical phase towards the first rigorous clinical trials. The compound shows legitimate potential, but intellectual honesty requires acknowledging that definitive clinical evidence is still lacking.

The next chapter will be written by the clinical trials under way. Their design, their rigour and their funding will determine whether methylene blue attains established therapeutic status or remains a promising scientific curiosity.

To explore current practical applications, consult our pages on validated everyday applications and innovative applications under exploration.